AC Immune shares surge 14.81% after-hours after amending Lilly collaboration, securing CHF10 million upfront and advancing Tau drug development.

AC Immune surged 14.81% in after-hours trading following the announcement of an amended license and collaboration agreement with Eli Lilly. The revised terms extend the partnership to develop new Tau aggregation inhibitor small molecules targeting Alzheimer’s and other neurodegenerative diseases. AC Immune received a CHF10 million upfront payment and is eligible for further milestone and royalty payments exceeding CHF1.7 billion. The amendment reflects growing scientific interest in intracellular Tau targeting and advances in AC Immune’s Morphomer platform, which has shown promising preclinical data. The collaboration, now expanded to include new lead candidates and back-up compounds, highlights significant progress and strengthens AC Immune’s pipeline, fueling investor optimism.